PureTech Health has presented data for product candidate ALV-107 showing durable pain control throughout a 24-hour study period, lasting at least 12 times longer than lidocaine at a comparable dose (ALV-107 16 mg/kg, conventional lidocaine 16 mg/kg), in a validated preclinical model for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).
Elite Pharmaceuticals has reported topline results from a pivotal bioequivalence fed study for SequestOx.
Alnylam Pharmaceuticals and Sanofi Genzyme have commenced Atlas Phase 3 clinical program for hemophilia treatment, fitusiran.
Entasis Therapeutics and Global Antibiotic Research and Development Partnership (GARDP) will initiate pivotal trials of oral antibiotic zoliflodacin (ETX0914) being developed to treat drug-resistant gonorrhea.
Prothena has reported that the first patient has been enrolled in PASADENA, a global Phase 2 study of PRX002/RG7935 in patients with early Parkinson's disease.
Zealand Pharma has started a multinational Phase 3 clinical trial of dasiglucagon in four countries (Austria, Germany, Canada and the US).
Daiichi Sankyo's pain drug mirogabalin has showed mixed results in phase 3 global clinical development program.
bluebird bio has released topline interim data from the initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study (ALD-102) evaluating its investigational gene therapy Lenti-D in under-18 boys with cerebral adrenoleukodystrophy (CALD).
Roche’s haemophilia A drug emicizumab has showed a significant effect in the phase III Haven 1 and Haven 2 studies.
Novartis’ heart drug ACZ885 (canakinumab) has met primary endpoint in the global phase III Canakinumab anti-inflammatory thrombosis outcomes (Cantos) study.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.